dc.contributor.author | Scherman, Peter | |
dc.date.accessioned | 2022-03-23T13:24:44Z | |
dc.date.available | 2022-03-23T13:24:44Z | |
dc.date.issued | 2022-03-23 | |
dc.identifier.isbn | 978-91-8009-638-6 (PRINT) | |
dc.identifier.isbn | 978-91-8009-639-3 (PDF) | |
dc.identifier.uri | https://hdl.handle.net/2077/70529 | |
dc.description.abstract | Background: Resection and/or ablation of colorectal liver metastases (CRLM) is increasingly common and long-term results are improving. In this thesis prognosis of CRLM is studied in a wide perspective, with focus on common clinical factors to consider in preoperative decision making.
Study I-III: Data on radically resected colorectal cancer (CRC) was col-lected from the Swedish Colorectal Cancer Registry (SCRCR) and patients also treated for CRLM were identified in the Swedish Registry for Liver Cancer (Sweliv). A total of 1325 patients were treated for CRLM with a 5-year relative survival (RS) >50%, also for patients ≥75 years of age. Com-plications from the primary tumor resection and primary tumor characteris-tics had a large impact on long-term survival after treatment of CRLM. Liver metastasis >20 mm, was associated with increased risk. Number of tumors was of less importance when tumor location was considered. Abla-tion doubled the risk of death within 5 years in a propensity score analysis. Postoperative complications (POC) were registered for 24% of all patients and were associated with inferior 5-year RS and prolonged hospital stay. Laparoscopic technique lowered the risk for POC.
Study IV-V: The study cohort was based on the randomized COLOFOL trial and included patients with recurrent disease after radically resected CRC. All recurrences within 5 years postoperatively were identified and medical files were scrutinized. Out of 2442 patients, 471 developed any kind of local recurrences or metachronous metastases of which 48% were treated with curative intent. Over 90% of the 235 patients with CRLM were assessed in multidisciplinary tumor boards, 123 (52%) were treated with curative intent with subsequent 5-year overall survival (OS) of 58%. High frequency follow-up after primary tumor resection was a positive prognostic factor for patients with CRLM.
Conclusion: Prognosis of CRLM depend on patient, primary tumor, met-astatic pattern, and choice of treatment. After multidisciplinary assessment, high resection rates and long-term survival are achievable. | en_US |
dc.language.iso | eng | en_US |
dc.relation.haspart | I. Scherman P, Syk I, Holmberg E, Naredi P, Rizell M. Influence of primary tumor and patient factors on survival in patients undergoing curative resection and treatment for liver metastases from colorectal cancer. BJS Open 2020;4(1):118-132. https://doi.org/10.1002/bjs5.50237 | en_US |
dc.relation.haspart | II. Scherman P, Syk I, Holmberg E, Naredi P, Rizell M. Impact of patient, primary tumor and metastatic pattern including tumor location on survival in patients undergoing ablation or resection for colorectal liver metastases: A population-based national cohort study. Eur J Surg Oncol 2021;47(2):375-383. https://doi.org/10.1016/j.ejso.2020.07.030 | en_US |
dc.relation.haspart | III. Scherman P, Syk I, Holmberg E, Naredi P, Rizell M. Risk factors for postoperative complications following resection of colorectal liv-er metastases and the impact on long-term survival: A population-based national cohort study. Manuscript, submitted. | en_US |
dc.relation.haspart | IV. Hansdotter P*, Scherman P*, Petersen S H, Mikalonis M, Holmberg E, Rizell M, Naredi P, Syk I, on behalf of the COLO-FOL study group. Patterns and resectability of colorectal cancer re-currences: outcome study within the COLOFOL trial. BJS Open 2021;5(4). https://doi.org/10.1093/bjsopen/zrab067
*These authors contributed equally to this paper | en_US |
dc.relation.haspart | V. Scherman P, Hansdotter P, Holmberg E, Petersen S, Rizell M, Naredi P, Syk I, on behalf of the COLOFOL study group. High re-section rates of colorectal liver metastases after standardized follow-up and multimodal management: an outcome study within the COLOFOL trial. Manuscript. | en_US |
dc.subject | Colorectal liver metastases | en_US |
dc.subject | Prognostic factors | en_US |
dc.subject | Primary tumor | en_US |
dc.subject | Resection | en_US |
dc.subject | Ablation | en_US |
dc.subject | Postoperative complications | en_US |
dc.subject | Resectability | en_US |
dc.subject | Follow-up | en_US |
dc.title | Curatively Intended Treatment of Colorectal Liver Metastases - Patient, Primary and Metastatic Pattern as Prognostic Factors | en_US |
dc.type | text | eng |
dc.type.svep | Doctoral thesis | eng |
dc.gup.mail | peter.scherman@gu.se | en_US |
dc.type.degree | Doctor of Philosophy | en_US |
dc.gup.origin | University of Gothenburg. Sahlgrenska Academy. | en_US |
dc.gup.department | Institute of Clinical Sciences. Department of Surgery | en_US |
dc.gup.defenceplace | Fredagen den 22 april 2022, kl. 13.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg | en_US |
dc.gup.defencedate | 2022-04-22 | |
dc.gup.dissdb-fakultet | SA | |